BRAF and Histiocytosis: These BRAF inhibitors have revolutionized therapy for patients with BRAF V600–mutant advanced melanoma and demonstrated promising results in patients with other BRAF mutation–harboring diseases, including histiocytosis, hairy cell leukemia, non–small cell lung cancer, and biliary cancer.